Sarepta Therapeutics (SRPT) Tightened 2026 Revenue Guidance, Is The Stock Still A Bargain?
Sarepta Therapeutics (SRPT) recently narrowed its 2026 total net product revenue guidance to a range of $1.2b to $1.3b and paired this with second quarter results and pipeline updates for rare disease programs.
See our latest analysis for Sarepta Therapeutics.
Against this backdrop of updated guidance and rare disease progress, Sarepta Therapeutics has seen a sharp 7 day share price return of 15.38% but its year to date share price return is still down 13.75%, echoing a much weaker 3 year total shareholder return that is down 83.87%.
If Sarepta’s recent moves have you thinking about where science and returns can meet, it might be worth scanning for other healthcare focused AI opportunities through the 43 healthcare AI stocks.
Sarepta Therapeutics now sits between a tighter revenue outlook and fresh enthusiasm around its rare disease pipeline. Is the recent 7 day jump a catch up to business fundamentals, or mainly a swing in sentiment that the valuation section can unpack further?
Most Popular Narrative: 15.1% Undervalued
Compared with Sarepta Therapeutics’ last close at $18.38, the most followed narrative pegs fair value at $21.65, which frames the recent rebound in a different light.
The analysts have a consensus price target of $21.65 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $5.0.
Want to see what sits behind that fair value for Sarepta Therapeutics? Analysts are factoring in a profit transition, shifting margins and a higher future earnings multiple. The detailed narrative shows how those moving parts connect.
Result: Fair Value of $21.65 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Sarepta Therapeutics still faces meaningful risks, including ongoing safety concerns around ELEVIDYS and high research and collaboration costs that could pressure margins if uptake remains cautious.
Find out about the key risks to this Sarepta Therapeutics narrative.
Next Steps
If this mix of risks and rewards around Sarepta Therapeutics feels finely balanced, take a closer look at the full picture and form your own view with the 1 key reward and 1 important warning sign
Looking for more investment ideas beyond Sarepta Therapeutics?
If Sarepta Therapeutics has sharpened your focus on where risk and reward can meet, do not stop here. Use the Simply Wall St Screener to spot fresh opportunities, compare quality signals and build a watchlist that fits your own investing style.
- Target potential mispricings by scanning companies that score well on quality and valuation with the 49 high quality undervalued stocks.
- Strengthen the defensive side of your portfolio by filtering for businesses with resilient finances through the 85 resilient stocks with low risk scores.
- Get ahead of the crowd by searching for under followed companies with solid fundamentals using the screener containing 20 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com